Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Hold” by Analysts
Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the eleven research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $24.14.
Several analysts have issued reports on ITCI shares. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Leerink Swann reaffirmed an “outperform” rating on shares of Intra-Cellular Therapies in a report on Monday, March 20th. Piper Jaffray Companies downgraded shares of Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $22.00 to $10.00 in a report on Monday, May 1st. Cantor Fitzgerald set a $29.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, May 11th. Finally, Ladenburg Thalmann Financial Services downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a report on Tuesday, May 2nd.
Intra-Cellular Therapies (NASDAQ ITCI) traded down 3.27% during trading on Monday, hitting $11.85. The company had a trading volume of 186,131 shares. The stock’s market capitalization is $514.53 million. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $45.20. The firm’s 50 day moving average is $10.83 and its 200-day moving average is $13.28.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.12. Intra-Cellular Therapies had a negative net margin of 27,180.94% and a negative return on equity of 29.74%. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.02 million. During the same period in the prior year, the business posted ($0.64) earnings per share. On average, equities analysts forecast that Intra-Cellular Therapies will post ($3.03) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in Intra-Cellular Therapies by 18.0% in the fourth quarter. State Street Corp now owns 972,868 shares of the biopharmaceutical company’s stock worth $14,686,000 after buying an additional 148,745 shares in the last quarter. Highbridge Capital Management LLC bought a new position in Intra-Cellular Therapies during the fourth quarter worth $166,000. Franklin Street Advisors Inc. NC increased its position in Intra-Cellular Therapies by 135.6% in the first quarter. Franklin Street Advisors Inc. NC now owns 26,060 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 15,000 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Intra-Cellular Therapies during the fourth quarter worth $574,000. Finally, Norges Bank bought a new position in Intra-Cellular Therapies during the fourth quarter worth $4,238,000. 67.55% of the stock is currently owned by institutional investors.
About Intra-Cellular Therapies
ITI Inc is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.